Silvia Fargion Selected Research

Chronic Hepatitis C

10/2021	Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
12/2017	Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.
3/2016	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
1/2014	Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients.
4/2013	IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C.
8/2012	The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
3/2011	Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.
3/2008	Iron genes, dysmetabolism and fibrosis in chronic hepatitis C.
1/2006	Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.
4/2003	Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Silvia Fargion Research Topics

Disease

57	Non-alcoholic Fatty Liver Disease 10/2023 - 02/2002
46	Fibrosis (Cirrhosis) 10/2023 - 05/2004
22	Insulin Resistance 01/2018 - 02/2002
17	Iron Overload 01/2021 - 01/2003
16	Liver Cirrhosis (Hepatic Cirrhosis) 10/2023 - 08/2007
16	Fatty Liver 10/2021 - 02/2002
15	Hemochromatosis (Bronze Diabetes) 01/2020 - 06/2002
13	Inflammation (Inflammations) 01/2021 - 08/2004
13	Liver Diseases (Liver Disease) 01/2021 - 08/2004
12	Hepatocellular Carcinoma (Hepatoma) 10/2020 - 05/2004
11	Chronic Hepatitis C 10/2021 - 05/2002
10	Hyperferritinemia 01/2021 - 10/2003
9	Infections 12/2017 - 07/2005
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2014 - 06/2007
6	Siderosis 01/2021 - 02/2002
5	Atherosclerosis 07/2023 - 03/2011
5	Hepatitis 12/2017 - 08/2004
5	Chronic Hepatitis (Chronic Active Hepatitis) 05/2008 - 05/2004
4	Type 2 Diabetes Mellitus (MODY) 11/2020 - 02/2012
4	Obesity 06/2018 - 06/2007
4	Hypertension (High Blood Pressure) 01/2017 - 09/2008
4	Alcoholic Fatty Liver 01/2017 - 08/2012
4	beta-Thalassemia (Cooley's Anemia) 09/2014 - 08/2007
3	Anemia 01/2021 - 08/2009
3	Abdominal Obesity 01/2017 - 06/2011
3	Hyperglycemia 02/2015 - 05/2012
2	Neoplasms (Cancer) 10/2021 - 10/2020
2	Dyslipidemias (Dyslipidemia) 01/2019 - 07/2014
2	Cryptogenic Cirrhosis 01/2017 - 02/2013
2	Chronic Hepatitis B 10/2013 - 02/2013
2	Iron Deficiencies 02/2013 - 02/2010
2	Alcoholism (Alcohol Abuse) 12/2012 - 01/2008
2	Glucose Intolerance 06/2011 - 02/2002
1	Weight Gain 01/2022
1	Liver Neoplasms (Liver Cancer) 10/2021
1	Dysbiosis 10/2021
1	Thalassemia 01/2021
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021
1	Cholelithiasis 01/2020
1	Portal Hypertension 01/2020

Drug/Important Bio-Agent (IBA)

40	IronIBA 01/2021 - 05/2002
21	Ferritins (Ferritin)IBA 01/2021 - 10/2003
15	EnzymesIBA 01/2020 - 02/2002
14	HepcidinsIBA 01/2020 - 08/2007
12	Glucose (Dextrose)FDA LinkGeneric 10/2023 - 06/2002
12	LipidsIBA 10/2021 - 02/2010
10	Transferrin (beta 2 Transferrin)IBA 01/2021 - 01/2003
9	Phospholipases (Phospholipase)IBA 11/2020 - 04/2010
9	Proteins (Proteins, Gene)FDA Link 10/2020 - 05/2008
8	Triglycerides (Triacylglycerol)IBA 01/2019 - 09/2008
7	CytokinesIBA 02/2022 - 02/2002
7	InterferonsIBA 12/2017 - 05/2002
7	Alanine Transaminase (SGPT)IBA 03/2016 - 09/2008
6	Transaminases (Aminotransferases)IBA 01/2022 - 09/2008
5	Messenger RNA (mRNA)IBA 06/2018 - 10/2003
5	Insulin (Novolin)FDA Link 10/2015 - 06/2007
4	AdiponectinIBA 01/2018 - 08/2012
4	Hormones (Hormone)IBA 10/2016 - 01/2012
3	Antiviral Agents (Antivirals)IBA 10/2021 - 03/2011
3	Ribavirin (Virazole)FDA LinkGeneric 01/2014 - 01/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2013 - 02/2002
3	AntioxidantsIBA 02/2010 - 07/2005
3	LDL CholesterolIBA 01/2008 - 12/2005
2	nasIBA 07/2023 - 01/2018
2	metal transporting protein 1 (ferroportin)IBA 01/2021 - 11/2010
2	CarbohydratesIBA 11/2020 - 10/2011
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2020 - 09/2010
2	ApolipoproteinsIBA 11/2020 - 07/2010
2	FructoseIBA 11/2020 - 01/2017
2	Peptides (Polypeptides)IBA 10/2020 - 07/2014
2	Sterol Esterase (Hormone-Sensitive Lipase)IBA 12/2019 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 01/2006
2	CholesterolIBA 06/2018 - 09/2015
2	AnticoagulantsIBA 01/2018 - 07/2014
2	Telomerase (Telomerase Reverse Transcriptase)IBA 08/2017 - 02/2013
2	Insulin ReceptorIBA 01/2017 - 03/2008
2	Methionine (L-Methionine)FDA Link 01/2017 - 04/2010
2	Biomarkers (Surrogate Marker)IBA 04/2016 - 06/2011
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016 - 09/2015
2	AdipokinesIBA 10/2015 - 06/2013
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 03/2014 - 06/2012
2	TransferasesIBA 03/2014 - 03/2011
2	adiponutrinIBA 10/2010 - 04/2010
2	Deferoxamine (Desferal)FDA LinkGeneric 02/2010 - 03/2008
1	Sodium-Glucose Transport ProteinsIBA 10/2023
1	SodiumIBA 10/2023
1	Bevacizumab (Avastin)FDA Link 02/2022
1	atezolizumabIBA 02/2022
1	Ceruloplasmin (Ferroxidase)IBA 01/2021
1	VitaminsIBA 11/2020
1	MicronutrientsIBA 11/2020
1	FatsIBA 11/2020
1	NeurotensinIBA 10/2020
1	Neurotensin Receptors (Neurotensin Receptor)IBA 10/2020

Therapy/Procedure

16	Therapeutics 02/2022 - 05/2002
3	Liver Transplantation 02/2013 - 05/2004
2	Renal Dialysis (Hemodialysis) 08/2009 - 01/2007
1	Immunotherapy 02/2022
1	Mediterranean Diet 01/2022
1	Ambulatory Care (Outpatient Care) 11/2020